Side effects observed in<unk> -treated persons in clinical trials with an incidence >5% and at least twice as common in<unk> -treated persons compared to those who received a placebo pill include abnormal dreams, abnormal ejaculation, anorexia, anxiety, asthenia, diarrhea, dry mouth, dyspepsia,<unk> u syndrome, impotence, insomnia, decreased libido, nausea, nervousness, pharyngitis, rash, sinusitis, somnolence, sweating, tremor, vasodilation, and yawning.<unk>  is considered the most stimulating of the SSRIs (that is, it is most prone to causing insomnia and agitation). It also appears to be the most prone of the SSRIs for producing dermatologic reactions (e.g. urticaria (hives), rash, itchiness, etc.). Sexual dysfunction Sexual dysfunction, including loss of libido, erectile dysfunction in men, lack of vaginal lubrication in women, and anorgasmia, are some of the most commonly encountered adverse effects of treatment with<unk>  and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is >70%. On 11 June 2019, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency concluded that there is a possible causal association between SSRI use and long-lasting sexual dysfunction that persists despite discontinuation of SSRI, including<unk> , and that the labels of these drugs should be updated to include a warning. Antidepressant discontinuation syndrome<unk> 's longer half-life makes it less common to develop antidepressant discontinuation syndrome following cessation of therapy, especially when compared to antidepressants with shorter half-lives such as paroxetine. Although gradual dose reductions are recommended with antidepressants with shorter half-lives, tapering may not be necessary with<unk> . Pregnancy Antidepressant exposure (including<unk>  is associated with shorter average duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g), and lower Apgar scores (by to and IKs that repolarise the cardiac action potential. Under certain circumstances, this can lead to prolongation of the QT interval, a measurement made on an electrocardiogram reflecting how long it takes for the heart to electrically recharge after each heartbeat. When<unk>  is taken alongside other drugs that prolong the QT interval, or by those with a susceptibility to long QT syndrome, there is a small risk of potentially lethal abnormal heart rhythms such as torsades de pointes. As of 2019, the drug reference site CredibleMeds lists<unk>  as leading to a conditional risk of arrhythmias. Further study of multiple SSRI medications noted the highest risk of QT prolongation occurred with citalopram and escitalopram.<unk>  did not alter the QT interval and had no clinically meaningful effects on the cardiac action potential.
Fluoxetine
Atomoxetine
Duloxetine
Dapoxetine
Edivoxetine
Vortioxetine
Bupropion
Citalopram